Hereditary haemorrhagic telangiectasia (HHT) is a rare genetic vascular disease that can significantly impair the quality of life of affected patients [1]. Medical management is mainly aimed at treating the symptoms and at preventing life-threatening complications, while a therapy for the disease is still missing. In this medical scenario, the availability of prognostic and therapeutic monitoring tools is strongly desirable for clinical practice. According to this, the use of biomarkers could be very helpful.
